425 related articles for article (PubMed ID: 17445544)
1. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
Walker GE; Marzullo P; Verti B; Guzzaloni G; Maestrini S; Zurleni F; Liuzzi A; Di Blasio AM
Obesity (Silver Spring); 2008 Sep; 16(9):1983-91. PubMed ID: 19186324
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots.
Kang JG; Park CY; Ihm SH; Yoo HJ; Park H; Rhee EJ; Won JC; Lee WY; Oh KW; Park SW; Kim SW
Metabolism; 2010 Jan; 59(1):46-53. PubMed ID: 19716145
[TBL] [Abstract][Full Text] [Related]
4. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor γ activation favours selective subcutaneous lipid deposition by coordinately regulating lipoprotein lipase modulators, fatty acid transporters and lipogenic enzymes.
Blanchard PG; Turcotte V; Côté M; Gélinas Y; Nilsson S; Olivecrona G; Deshaies Y; Festuccia WT
Acta Physiol (Oxf); 2016 Jul; 217(3):227-39. PubMed ID: 26918671
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
7. Cidea is associated with lipid droplets and insulin sensitivity in humans.
Puri V; Ranjit S; Konda S; Nicoloro SM; Straubhaar J; Chawla A; Chouinard M; Lin C; Burkart A; Corvera S; Perugini RA; Czech MP
Proc Natl Acad Sci U S A; 2008 Jun; 105(22):7833-8. PubMed ID: 18509062
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
Li J; Xue YM; Zhu B; Pan YH; Zhang Y; Wang C; Li Y
J Diabetes Res; 2018; 2018():4627842. PubMed ID: 30225267
[TBL] [Abstract][Full Text] [Related]
9. Adipocyte differentiation-related protein and OXPAT in rat and human skeletal muscle: involvement in lipid accumulation and type 2 diabetes mellitus.
Minnaard R; Schrauwen P; Schaart G; Jorgensen JA; Lenaers E; Mensink M; Hesselink MK
J Clin Endocrinol Metab; 2009 Oct; 94(10):4077-85. PubMed ID: 19602560
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis.
Han SJ; Kang ES; Hur KY; Kim HJ; Kim SH; Yun CO; Choi SE; Ahn CW; Cha BS; Kang Y; Lee HC
Horm Res; 2008; 70(3):165-73. PubMed ID: 18663317
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone regulates IL-6-stimulated lipolysis in porcine adipocytes.
Yang Y; Yang G
Biochem Cell Biol; 2010 Oct; 88(5):853-60. PubMed ID: 20921996
[TBL] [Abstract][Full Text] [Related]
12. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
[TBL] [Abstract][Full Text] [Related]
13. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
Lupi R; Del Guerra S; Marselli L; Bugliani M; Boggi U; Mosca F; Marchetti P; Del Prato S
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E560-7. PubMed ID: 14625208
[TBL] [Abstract][Full Text] [Related]
15. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
16. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
17. Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.
Punthakee Z; Alméras N; Després JP; Dagenais GR; Anand SS; Hunt DL; Sharma AM; Jung H; Yusuf S; Gerstein HC
Diabet Med; 2014 Sep; 31(9):1086-92. PubMed ID: 24890138
[TBL] [Abstract][Full Text] [Related]
18. Reduced mRNA and protein expression of perilipin A and G0/G1 switch gene 2 (G0S2) in human adipose tissue in poorly controlled type 2 diabetes.
Nielsen TS; Kampmann U; Nielsen RR; Jessen N; Orskov L; Pedersen SB; Jørgensen JO; Lund S; Møller N
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1348-52. PubMed ID: 22535977
[TBL] [Abstract][Full Text] [Related]
19. Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
Jia D; Yamamoto M; Otani M; Otsuki M
Metabolism; 2004 Apr; 53(4):405-13. PubMed ID: 15045684
[TBL] [Abstract][Full Text] [Related]
20. Increased lipolysis in adipose tissues is associated with elevation of systemic free fatty acids and insulin resistance in perilipin null mice.
Zhai W; Xu C; Ling Y; Liu S; Deng J; Qi Y; Londos C; Xu G
Horm Metab Res; 2010 Apr; 42(4):247-53. PubMed ID: 20091459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
